Ibogaine drug trials will hit regulatory roadblocks — either the FDA (US drug regulator) will freeze trials pending better heart safety data, or the DEA (US drug enforcement agency) will block rescheduling efforts — before the end of 2026. These aren't obstacles that can be ignored; they force companies to redesign trials or develop chemically similar alternatives.
Concurrent cardiac safety publications give both FDA and DEA documented scientific cover to act. FDA's most probable mechanism is program-specific IND holds rather than field-wide guidance. DEA opposition to rescheduling is structurally likely regardless of new data. The combined probability that at least one of these mechanisms produces a tangible bottleneck (hold letter, formal opposition filing, public communication) before year-end is substantially higher than either individual event alone. Dissenting agents (MAPS researcher, veterans advocate) correctly note political pressure cuts the other way, but regulatory inertia favors delay. Resolve date moved from August 2026 to December 2026 to match the more specific child prediction and allow adequate observation window.